EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sight Sciences's enterprise value is $99.73 Mil.
Sight Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-43.75 Mil. Therefore, Sight Sciences's EV-to-EBITDA for today is -2.28.
The historical rank and industry rank for Sight Sciences's EV-to-EBITDA or its related term are showing as below:
SGHT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -37.77 Med: -3.8 Max: 0.66
Current: -2.28
During the past 7 years, the highest EV-to-EBITDA of Sight Sciences was 0.66. The lowest was -37.77. And the median was -3.80.
SGHT's EV-to-EBITDA is ranked worse than 100% of 493
companies
in the Medical Devices & Instruments industry
Industry Median: 15.45
vs SGHT: -2.28
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Sight Sciences EV-to-EBITDA Historical Data
The historical data trend for Sight Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sight Sciences's EV-to-EBITDA
For the Medical Devices subindustry, Sight Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sight Sciences's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sight Sciences's EV-to-EBITDA falls into.
Sight Sciences's current Enterprise Value is $99.73 Mil.
Sight Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sight Sciences's PE Ratio (TTM) for today is calculated as:
Sight Sciences's share price for today is $3.28.
Sight Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.980.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Sight Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGHT has been successfully added to your 